Page 3 - திரோஎகே குழு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Dec 11 2020 Read 1087 Times
AstraZeneca AB has signed an agreement with Netherlands-based HALIX B.V for large-scale commercial drug substance manufacture of AZD1222, the adenovirus vector-based COVID-19 vaccine, co-invented by the University of Oxford and its spin-out company Vaccitech.
Under the agreement, HALIX, one of the original partners in the University of Oxford’s consortium, will provide commercial manufacturing of drug substance at its cGMP facility at the Leiden Bio Science Park in the Netherlands, which has been expanded with two additional viral vector production lines.
Alex Huybens, Chief Operations Officer, states, “Building on the solid foundations made with the University of Oxford, it’s our pleasure to expand our manufacturing support of AZD1222 with AstraZeneca. Through the consortium, the partners are bringing their collective expertise and manufacturing capabilities to support vaccine production and combat this evolving crisis.” ....

Alex Huybens , University Of Oxford , Droege Group , Leiden Bio Science Park , Chief Operations Officer , Leiden Boi Science Park , பல்கலைக்கழகம் ஆஃப் ஆக்ஸ்ஃபர்ட் , திரோஎகே குழு , தலைமை செயல்பாடுகள் அதிகாரி ,